A UK alliance between data scientists, clinical researchers, and community opticians hopes to develop an AI to predict dementia during an eye test.

FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

At the opposite end of the spectrum, we have our Non-Competitive pitches. Roughly 10% of all pitches were at least 95% likely ...

Eye patients sometimes assume that their vision screenings required for obtaining a driver’s license or certain ...